HOOKIPA Pharma to Report Fourth Quarter and Full Year 2022 Financial Results and Provide a Corporate Update on March 15, 2023
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced plans to release its fourth quarter and full year 2022 financial results on March 15, 2023, before the market opens.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
HOOKIPA Pharma Inc. (NASDAQ: HOOK) announced plans to release its fourth quarter and full year 2022 financial results on March 15, 2023, before the market opens. The company will host a live conference call at 8:30 AM ET to discuss these results and provide a corporate update. HOOKIPA specializes in developing immunotherapeutics based on its proprietary arenavirus platform, targeting cancers and viral diseases such as HBV and HIV. The company collaborates with notable partners including Roche and Gilead. For access details, participants can find the webcast link on HOOKIPA's investor relations page.
Positive
- Upcoming financial results expected to provide insights on company performance.
- Investments in immunotherapies targeting significant health issues, including HPV-related cancers and viral diseases.
- Collaboration with major pharmaceutical companies like Roche and Gilead may enhance research and development capabilities.
Negative
- None.
Details
News Market Reaction – HOOK
The recorded move for HOOK in the trading session of this news was +0.11%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
NEW YORK and VIENNA, March 08, 2023 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (NASDAQ: HOOK, ‘HOOKIPA’), a company developing a new class of immunotherapeutics based on its proprietary arenavirus platform, today announced that it will release fourth quarter and full year 2022 financial results before the market opens on Wednesday, March 15, 2023. The Company will host a live conference call and webcast at 8:30 AM ET to discuss its financial results and provide a corporate update.
| Conference Call & Webcast: | |||
| Date: | March 15, 2023 | ||
| Time: | 8:30 AM ET | ||
| USA Dial In: | +1-800-715-9871 | ||
| UK Dial In: | 0800-260-6466 | ||
| Austria Dial In: | +43 800-070-441 | ||
| Conference ID: | 7669853 | ||
| Webcast: | Link | ||
The webcast and the presentation will also be available within the Investors & Media section of HOOKIPA’s website at https://ir.hookipapharma.com/events.
About HOOKIPA
HOOKIPA Pharma Inc. (NASDAQ: HOOK) is a clinical-stage biopharmaceutical company focused on developing novel immunotherapies, based on its proprietary arenavirus platform, which are designed to mobilize and amplify targeted T cells and thereby fight or prevent serious disease. HOOKIPA’s replicating and non-replicating technologies are engineered to induce robust and durable antigen-specific CD8+ T cell responses and pathogen-neutralizing antibodies. HOOKIPA’s pipeline includes its wholly owned investigational arenaviral immunotherapies targeting Human Papillomavirus 16-positive cancers, prostate cancers, and other undisclosed programs. HOOKIPA is collaborating with Roche on an arenaviral immunotherapeutic for KRAS-mutated cancers. In addition, HOOKIPA aims to develop functional cures of HBV and HIV in collaboration with Gilead.
Find out more about HOOKIPA online at www.hookipapharma.com.
| For further information, please contact: | |||
| Media | Investors | ||
| Instinctif Partners | Matt Beck | ||
| hookipa@instinctif.com | Executive Director - Investor Relations | ||
| +44 (0)20 7457 2020 | matthew.beck@hookipapharma.com | ||
| +1 917 209 6886 | |||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.